Dr Apostolos Zarros, physician, MRes, PhD, PhD, MAPS, MRSB
Visiting Professor, University of Babylon
Research Associate, University of Glasgow
Co-Founder and Director, Ellot & Saros Limited
Fellow, The Royal Numismatic Society
DOWNLOADING (as a .pdf file):
[CV-AZarros] (last update: not available)
I was born in Greece (1983) and was raised in a small coastal town by the Corinthian Gulf. Inspired to establish a family tradition, I completed my medical studies at the Medical School of the National and Kapodistrian University of Athens. Throughout my studies I worked as an Undergraduate Research Assistant in the laboratory of Associate Professor Stylianos Tsakiris, where I had the chance to conduct a significant amount of experimental work focussing on rat brain-derived membrane-bound enzyme activities within the context of experimentally-simulated toxic and metabolic encephalopathies. Part of this work has formed the basis for the award of a PhD (by published work / retrospective) by the University of Bolton (supervised by Professors Elias Siores and Martin Grootveld).
In 2011 I was awarded a studentship within the prestigious Wellcome Trust PhD Programme at the University of Glasgow. As part of this Programme, I completed the MRes in Molecular Functions in Disease before proceeding to pursue a PhD in Neuropathology at the Institute of Cardiovascular and Medical Sciences of the University of Glasgow (supervised by Professors George S. Baillie and William Cushley). My PhD Thesis in Neuropathology focused on the development and assessment of in vitro simulation approaches to intracerebral haemorrhage, and incorporated the cytomorphological characterization and the real-time cellular response profiling of an immortalized embryonic murine hippocampal cell-line (mHippoE-14).
In 2015 I was appointed as a Research Associate at the Research Department of Pharmaceutics of the University College London (UCL) School of Pharmacy, and participated in an ambitious consortium project aiming to develop antibody-bearing nanoparticles that could be delivered to the brain via the intranasal route. While at this position, I conducted pharmacokinetic studies on the intranasal-to-brain delivery of nanoparticles in rodents, and undertook teaching training through courses offered by the UCL Centre for Advancing Learning and Teaching. After resigning from this appointment (2016), I had the honour to serve as a Research Assistant to Professor Tilli Tansey OBE at the History of Modern Biomedicine Research Group of the Queen Mary University of London, and to contribute to the Group’s research activities and editorial work on the Wellcome Trust-funded Witness Seminar transcript series entitled “Wellcome Witnesses to Contemporary Medicine”, and the interview transcripts’ compiling “Voices of Modern Biomedicine” series.
In 2015 I also founded “Ellot & Saros Limited” along with Dr Christina Elliott, and served as the company’s Director ever since. After gradually organizing the core elements of the company’s publishing activity, I launched (2017) the book-series “Nosos” as its Editor. Since then, along with “Nosos”, the company publishes a selected number of books, textbooks, yearbooks, encyclopaedias and proceedings of medical, biomedical and pharmaceutical interest.
In 2017 I was offered a Visiting Professorship at the College of Pharmacy of the University of Babylon, where in collaboration with Assistant Professor Hussam W. Al-Humadi, I have the pleasure to contribute to the research, teaching and curriculum enrichment activities of the College.
In 2017 I was also appointed as a Research Associate at the Institute of Cancer Sciences of the University of Glasgow, where I work under Professor Anthony Chalmers on an exciting 2-year project funded by AstraZeneca; the project will contribute to the understanding of the impact of ataxia-telangiectasia mutated (ATM) kinase inhibition on radiation-induced neuropathology, through imaging, behavioural, histopathological, cellular and molecular studies.
My primary research focus lies within the field of Experimental Medicine; specifically, on establishing a framework of theoretical principles and technical parameters that could be used as a basis for the development and assessment of in vitro simulation approaches to brain diseases (with an emphasis on astrocytic tumours, encephalopathies and neurotrauma-associated pathological entities) towards the delivery of more robust drug-screening tools. I recently coined the term “neuropathopoiesis” in order to summarize the priorities and vision of this effort (NeuroToxicology 2014; 44: 365).
My research interests also focus on: (i) the coincidental factors that shape pharmaceutical innovation, (ii) the role of sodium / potassium adenosine triphosphatase (Na+,K+-ATPase) as a cell type-specific determinant of neuropathogenesis, (iii) the molecular mechanisms underlying experimental and human neurocarcinogenesis, and (iv) the prerequisites for a successful implementation of dedicated research within the undergraduate medical curriculum.
My CV includes 66 articles indexed in PubMed and a number of further published works.
I maintain the membership status of the Academy of Pharmaceutical Sciences (MAPS), the British Pharmacological Society, the British Society for the History of Pharmacy, the In Vitro Toxicology Society, and the Royal Society of Biology (MRSB). I am also a Fellow of The Royal Numismatic Society.